Read more

August 13, 2024
1 min watch
Save

VIDEO: Study investigates novel therapy for penetration of pediatric brain tumors

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

PHILADELPHIA — In this video, Cassie Kline, MD, MAS, discusses the results of the PNOC016 trial she presented at International Symposium on Pediatric Neuro-Oncology.

The study observed the intratumoral pharmacokinetics and pharmacodynamic results of fimepinostat (Curis) in treating high-risk brain tumors in children and young adults with newly diagnosed diffuse intrinsic pontine gliomas, recurrent medulloblastoma or recurrent high-grade gliomas.

“[These] novel clinical trials [explore] not just the impact of drug on survival but [look] at intratumoral drug penetration and pharmacodynamic markers of response and [present] on ways in which we should be thinking about trial design and how we are answering or addressing questions of ‘how’ or ‘why’ a drug is working,” Kline, a pediatric neuro-oncology attending and director of neuro-oncology clinical research at Children’s Hospital of Philadelphia, said.

Reference:

  • Kline C, et al. Abstract TRLS-07. Presented at: International Symposium on Pediatric Neuro-Oncology; June 28-July 2, 2024; Philadelphia.